newsfilter
← Latest News
GlobeNewswire·

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million

-- 10,000 participant randomized Phase 2b study will evaluate Gritstone's self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus other viral targets with an approved vaccine against COVID-19 -- --